Nhwa Pharma. Corporation

Huazhong University of Science and Technology

Jiangsu Nhwaluokang Pharmceutical Research and Development Co., Ltd.

Shanghai Institute of Pharmaceutical Industry

Wuhan Jiayu Technology Co., Ltd.

Xiangqing Xu

Guisen Zhang

Minquan Yu

Song Zhao

Yin Chen

Bifeng Liu

Shicheng Liu

Jianqi Li

Guan Zhong Wang

Xin Liu

Yinli Qiu

Tao Wang

Qingeng Li

Xiangping Yang

Guisheng Zhang

Lingguo Zeng

Yali Li

Xiaowen Chen

Heng Zhang

Yanqin Ma

Shixia Zhou

Lin Guo

Yumei Wang

Shuming Hu

Linjie Zhang

Peng Xie

Jianyong Xie

Yu Lan

Xiaojun Feng

Xinghua Liu

Zhiqiang Liu

Qiang Guo

Liang Ren

Tan Zhang

Yifang Zhang

Xudong Cao

Guan Wang

The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases. 

Fused heterocyclic compound derivative and application thereof

The present invention discloses an etomidate derivative of Formula 1, or a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, a pharmaceutical composition and a kit comprising the same, as well as intermediates and methods for preparing the same, and use thereof. The etomidate derivative of the present invention not only has good anesthetic activity, rapid onset, and short duration of action, but also shows little inhibition to the secretion of corticosteroids in animals, and therefore has both favorable anesthetic effect and safety profiles. 

Etomidate derivative and intermediate, preparation method and use thereof

The present invention relates to 3-[(benzo[d][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine compounds of formula I or pharmaceutically acceptable salts thereof and use thereof. The compound may be used to prepare an antidepressant agent. 

3-[(Benzo[D][1,3]dioxolan-4-yl)-oxy]-3-arylpropylamine type compounds and applications thereof

The present invention relates to a new benzodiazepine derivative, pharmaceutically acceptable salt thereof, preparation method therefor, and use thereof. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of the present invention have obvious anesthetic effect and low toxicity in body, thereby enhancing the medication safety. The benzodiazepine derivative and the pharmaceutically acceptable salt thereof of the present invention have sedative, hypnotic, and anesthetic effect, and can be used as sedative, hypnotic, and anesthetic drugs.

Benzodiazepine derivative and use thereof

The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases. 

Benzopyrone derivative and use thereof

Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds are central analgesics regulating 5-hydroxytrptamine, and also are novel antidepressants regulating 5-hydroxytrptamine. This class of compounds also has less toxic and side effects and a higher safety range. The 3-cyanoanilinoalkylarylpiperazine derivative is a compound shown as formula (III) or free base or salt thereof: 

3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs

Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. EDis lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while EDis higher and therapeutic index is greater in animal models of catalepsy. 

Alicyclic[c] benzopyrone derivatives and uses thereof

The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system. 

[1,3,4] oxadiazole derivative and application thereof

The invention relates to a substituted phenylpiperazine aryl alkanol derivative represented by the following general formula and its salt and hydrate, wherein Cand Crepresent chiral carbon atoms, and the compound is one of the six isomers: (1RS, 2SR), (1RS, 2RS), (1R, 2S), (1S, 2S), (1R, 2R) or (1S, 2R); and R, R, R, Rand Ar are as defined in the specification. The derivative is non-opioid analgesic, has good analgesic effect and relatively small side effects. The invention also relates to a composition comprising the derivative and its use.

Substituted phenylpiperazinyl aralkylalcohol derivatives, pharmaceutical compositions containing such derivatives and uses thereof

The use of aryl piperazines of formula (I) in manufacturing a medicament for treating acute pain, neuropathic pain or receptive nociceptive pain in mammals including human beings is disclosed. 

Use of aryl piperazine derivatives in manufacturing medicants for treating pain

Growing community of inventors

Xuzhou, China

Xiangqing Xu